A detailed history of Kbc Group Nv transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Kbc Group Nv holds 5,982 shares of IOVA stock, worth $51,146. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,982
Previous 5,982 -0.0%
Holding current value
$51,146
Previous $48,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 17, 2024

BUY
$7.78 - $14.19 $12,502 - $22,803
1,607 Added 36.73%
5,982 $48,000
Q1 2024

May 08, 2024

SELL
$7.59 - $17.47 $1,502 - $3,459
-198 Reduced 4.33%
4,375 $65,000
Q4 2023

Feb 13, 2024

BUY
$3.3 - $8.89 $15,090 - $40,653
4,573 New
4,573 $37,000
Q4 2020

Feb 10, 2021

SELL
$28.04 - $50.26 $16,824 - $30,156
-600 Closed
0 $0
Q4 2019

Feb 11, 2020

BUY
$17.95 - $29.41 $6,821 - $11,175
380 Added 172.73%
600 $17,000
Q2 2019

Dec 03, 2019

BUY
$9.78 - $24.52 $2,151 - $5,394
220 New
220 $5,000

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.35B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Kbc Group Nv Portfolio

Follow Kbc Group Nv and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.